Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia

Nirali N. Shah, Michael J. Borowitz, Nancy C. Robey, Christopher J. Gamper, Heather J. Symons, David M. Loeb, Alan S. Wayne, Allen R. Chen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Outcomes are poor for patients with hematologic malignancies who experience overt relapse after allogeneic hematopoietic stem cell transplantation (HCT). Data on outcomes of post-transplantation minimal residual disease (MRD) are limited. In this single-institution, retrospective cohort analysis of children with acute leukemia and myelodysplastic syndrome, we document the pattern of relapse with a primary focus on outcomes of post-transplantation MRD. Forty of 93 patients (43%) who underwent a first allogeneic HCT and had systematic pretransplantation and post-transplantation MRD evaluations at +30, +60, +90, +180 days and +1 and +2 years post-transplantation experienced relapse. The median time to relapse was 4.8 months post-transplantation, with a median survival of 4 months post-relapse. Despite frequent, systematic, routine post-HCT disease restaging evaluation, 31 patients (78%) presented with overt disease at the time of relapse. Seven patients with acute leukemia who had post-transplantation MRD presented at a median of 1 month post-transplantation. Owing to rapid disease progression or treatment-related mortality, there was no improvement in survival in those patients whose leukemia was detected in a state of MRD post-transplantation. Our results suggest that early intervention strategies targeting post-transplantation MRD for relapse prevention in acute leukemia may not be feasible.

Original languageEnglish (US)
Pages (from-to)1000-1007
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number7
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Residual Neoplasm
Leukemia
Transplantation
Recurrence
Hematopoietic Stem Cell Transplantation
Survival
Myelodysplastic Syndromes
Hematologic Neoplasms
Secondary Prevention
Disease Progression
Cohort Studies
Mortality

Keywords

  • Allogeneic hematopoietic cell transplantation
  • Leukemia
  • Minimal residual disease
  • Pediatrics
  • Relapse

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia. / Shah, Nirali N.; Borowitz, Michael J.; Robey, Nancy C.; Gamper, Christopher J.; Symons, Heather J.; Loeb, David M.; Wayne, Alan S.; Chen, Allen R.

In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 7, 01.01.2014, p. 1000-1007.

Research output: Contribution to journalArticle

Shah, Nirali N. ; Borowitz, Michael J. ; Robey, Nancy C. ; Gamper, Christopher J. ; Symons, Heather J. ; Loeb, David M. ; Wayne, Alan S. ; Chen, Allen R. / Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia. In: Biology of Blood and Marrow Transplantation. 2014 ; Vol. 20, No. 7. pp. 1000-1007.
@article{cfe318fb40c84853b69e7605ac537cd6,
title = "Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia",
abstract = "Outcomes are poor for patients with hematologic malignancies who experience overt relapse after allogeneic hematopoietic stem cell transplantation (HCT). Data on outcomes of post-transplantation minimal residual disease (MRD) are limited. In this single-institution, retrospective cohort analysis of children with acute leukemia and myelodysplastic syndrome, we document the pattern of relapse with a primary focus on outcomes of post-transplantation MRD. Forty of 93 patients (43{\%}) who underwent a first allogeneic HCT and had systematic pretransplantation and post-transplantation MRD evaluations at +30, +60, +90, +180 days and +1 and +2 years post-transplantation experienced relapse. The median time to relapse was 4.8 months post-transplantation, with a median survival of 4 months post-relapse. Despite frequent, systematic, routine post-HCT disease restaging evaluation, 31 patients (78{\%}) presented with overt disease at the time of relapse. Seven patients with acute leukemia who had post-transplantation MRD presented at a median of 1 month post-transplantation. Owing to rapid disease progression or treatment-related mortality, there was no improvement in survival in those patients whose leukemia was detected in a state of MRD post-transplantation. Our results suggest that early intervention strategies targeting post-transplantation MRD for relapse prevention in acute leukemia may not be feasible.",
keywords = "Allogeneic hematopoietic cell transplantation, Leukemia, Minimal residual disease, Pediatrics, Relapse",
author = "Shah, {Nirali N.} and Borowitz, {Michael J.} and Robey, {Nancy C.} and Gamper, {Christopher J.} and Symons, {Heather J.} and Loeb, {David M.} and Wayne, {Alan S.} and Chen, {Allen R.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2014.03.021",
language = "English (US)",
volume = "20",
pages = "1000--1007",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia

AU - Shah, Nirali N.

AU - Borowitz, Michael J.

AU - Robey, Nancy C.

AU - Gamper, Christopher J.

AU - Symons, Heather J.

AU - Loeb, David M.

AU - Wayne, Alan S.

AU - Chen, Allen R.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Outcomes are poor for patients with hematologic malignancies who experience overt relapse after allogeneic hematopoietic stem cell transplantation (HCT). Data on outcomes of post-transplantation minimal residual disease (MRD) are limited. In this single-institution, retrospective cohort analysis of children with acute leukemia and myelodysplastic syndrome, we document the pattern of relapse with a primary focus on outcomes of post-transplantation MRD. Forty of 93 patients (43%) who underwent a first allogeneic HCT and had systematic pretransplantation and post-transplantation MRD evaluations at +30, +60, +90, +180 days and +1 and +2 years post-transplantation experienced relapse. The median time to relapse was 4.8 months post-transplantation, with a median survival of 4 months post-relapse. Despite frequent, systematic, routine post-HCT disease restaging evaluation, 31 patients (78%) presented with overt disease at the time of relapse. Seven patients with acute leukemia who had post-transplantation MRD presented at a median of 1 month post-transplantation. Owing to rapid disease progression or treatment-related mortality, there was no improvement in survival in those patients whose leukemia was detected in a state of MRD post-transplantation. Our results suggest that early intervention strategies targeting post-transplantation MRD for relapse prevention in acute leukemia may not be feasible.

AB - Outcomes are poor for patients with hematologic malignancies who experience overt relapse after allogeneic hematopoietic stem cell transplantation (HCT). Data on outcomes of post-transplantation minimal residual disease (MRD) are limited. In this single-institution, retrospective cohort analysis of children with acute leukemia and myelodysplastic syndrome, we document the pattern of relapse with a primary focus on outcomes of post-transplantation MRD. Forty of 93 patients (43%) who underwent a first allogeneic HCT and had systematic pretransplantation and post-transplantation MRD evaluations at +30, +60, +90, +180 days and +1 and +2 years post-transplantation experienced relapse. The median time to relapse was 4.8 months post-transplantation, with a median survival of 4 months post-relapse. Despite frequent, systematic, routine post-HCT disease restaging evaluation, 31 patients (78%) presented with overt disease at the time of relapse. Seven patients with acute leukemia who had post-transplantation MRD presented at a median of 1 month post-transplantation. Owing to rapid disease progression or treatment-related mortality, there was no improvement in survival in those patients whose leukemia was detected in a state of MRD post-transplantation. Our results suggest that early intervention strategies targeting post-transplantation MRD for relapse prevention in acute leukemia may not be feasible.

KW - Allogeneic hematopoietic cell transplantation

KW - Leukemia

KW - Minimal residual disease

KW - Pediatrics

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84902119213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902119213&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.03.021

DO - 10.1016/j.bbmt.2014.03.021

M3 - Article

VL - 20

SP - 1000

EP - 1007

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 7

ER -